Q32 Bio Profit Margin

Q32 Bio's profit margin stands at 62.87% as of June 2026. That is above the Healthcare sector average of 13.89%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Q32 Bio sits higher the Healthcare benchmark (13.89%) with a profit margin of 62.87%. That is roughly 352.6% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of 62.87% for Q32 Bio means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Q32 Bio's profit margin evolved across reporting periods, while the comparison chart places QTTB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, profit margin is commonly used to spot outliers. Q32 Bio's reading of 62.87% (sector avg 13.89%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.